World TB Day arrives every year on the twenty-fourth of March carrying statistics, press releases, and renewed pledges. What it rarely carries is her face. She came in through the emergency doors on a Tuesday, young and visibly fit, the kind of person nobody immediately associates with serious illness. An athlete. She had been coughing for weeks and had run out of explanations for why she could not catch her breath the way she used to. The chest X-ray told us what she had not yet let herself believe. We put in a chest drain that same evening.
She stayed for weeks. Long enough for us to know her a little. Long enough to watch the restlessness set in.
The Chest Drain, the Track, and the Diagnosis She Left Behind
She left against medical advice. There was a track event abroad, she told us, something she had trained toward across an entire season. We documented everything carefully, explained the risks plainly, and watched her sign the discharge papers with the focused calm of someone who had already made up her mind. She promised to follow up. She never did. No calls answered. No appointments kept. No word at all.
We talked about her the way clinical teams do when a case does not resolve cleanly. We wondered what became of her. Whether she competed. Whether the cough returned somewhere far from home, in a country where nobody had her records. The not knowing carries its own weight, and on World TB Day especially, I find myself returning to her face in that bed, already angled toward the door.
Her story is not unusual in its shape. The details change but the pattern holds. Tuberculosis consistently meets people at the intersection of their most urgent competing priorities. Understanding why people delay is not a question of patient compliance. It is a question of what we have built, and what we have failed to build, around the moment a person first suspects something is wrong.
Why the System Loses People Before They Begin
Think about what it actually takes to get tested for TB. You need time away from work, which for many means income lost with no guarantee of replacement. You need transport, which in settings where clinics are distant can consume an entire day for a single appointment. You need to walk into a facility and say, out loud, that you have been coughing for three months and you are frightened. And you need to do all of this while carrying the social weight that tuberculosis still attracts in many communities.
Shame is a vastly underestimated driver of late presentation, and this is a conversation that belongs at the centre of every World TB Day discussion. TB carries a stigma rooted in associations with poverty and moral failure, none of which are accurate and all of which persist. People delay because they do not want to be seen entering a TB clinic. They delay because misinformation fills every gap the health system leaves open. In communities with low trust in formal healthcare, those gaps are wide and deep.
Transport is a barrier that rarely receives the serious policy attention it deserves. For a person managing a chronic cough while working a physical job, travelling hours to a facility, waiting, being seen, collecting medication, and returning is not a minor inconvenience. It is a full undertaking that repeats across a treatment course lasting months. On World TB Day, the distance between a patient’s home and the nearest diagnostic centre deserves a seat at every planning table.
Workplace fear is another structural driver of delay. Many people with TB symptoms continue working because stopping is financially impossible. They worry, often with good reason, that disclosure will cost them their position. They manage symptoms quietly and deteriorate slowly in plain sight. Our athlete was not hiding poverty. She was protecting a competitive identity, a season of training, a future she had built her whole body toward. TB did not fit into that future, so she negotiated it away as long as she possibly could.
What Better Care Actually Looks Like
The answer to late presentation is not louder messaging. It is redesigning the conditions under which people seek care in the first place. Community-based screening programmes that bring testing into workplaces, markets, schools, and places of worship consistently find cases that would otherwise present late or not at all. The evidence for active case finding is strong. What is often missing is the sustained funding and political commitment to implement it beyond short-term pilots. World TB Day is a useful moment to ask what happened to last year’s screening commitments.
Workplace policies matter more than most employers appreciate. A clear, confidential protocol that protects an employee’s position during TB diagnosis and treatment removes one of the most significant barriers to early testing. This is not generosity. It is an investment in a workforce and a community. TB spreads in shared spaces. An employer who makes testing safer is protecting everyone in the building, not just the person who is ill.
Family support is the variable that clinical systems most consistently underestimate. A person who has someone at home who understands the diagnosis, helps manage the treatment schedule, and reduces the isolation of illness is significantly more likely to complete treatment. On World TB Day, the conversation about care must extend past the clinic and into the household, because that is where much of the real treatment happens.
Now here is where the science has moved in ways that genuinely matter. For years, treating drug-resistant TB meant eighteen months or longer, daily injections that caused hearing loss and kidney damage, and side effect profiles so demanding that adherence was difficult even for the most determined patients. That picture has changed substantially, and World TB Day 2025 is an important moment to say so clearly.
The BPaLM regimen, which combines:
- Bedaquiline,
- Pretomanid,
- Linezolid, and
- Moxifloxacin,
is a six-month fully oral treatment for multidrug-resistant TB showing success rates of approximately 89 percent. No injections. Dramatically shorter duration.
The BDLLfxC regimen, combining
- Bedaquiline,
- Delamanid,
- Linezolid,
- Levofloxacin, and
- Clofazimine,
is now the WHO-recommended first-line approach for MDR and rifampicin-resistant TB. It covers even pre-extensively drug-resistant cases that previously had very limited options.
These are not incremental adjustments. Moving from eighteen months of injections to six months of oral tablets transforms what treatment asks of a person. It does not eliminate the barriers of cost, access, and stigma. But it changes the calculation for someone hesitating about whether to begin. Six months is a manageable horizon in a way that eighteen simply is not. On World TB Day, that shift deserves to be named loudly and often.
What remains is the gap between what is possible in clinical trials and what reaches the places carrying the highest TB burden. New medicines cost more. Regulatory approval moves unevenly across health systems. Diagnostics for drug resistance are not universally available, which means some patients are still started on the wrong regimen because the right test was not accessible. Naming that gap honestly is the prerequisite for closing it.
Our athlete is somewhere in that gap. Between what medicine can now offer and what the world has so far managed to deliver. Between a treatment course that has become genuinely survivable and a system that still loses people at every junction before they reach it. We never heard from her again. But I think about what would need to be different for someone like her to stay. Shorter treatment. Flexible appointments. A workplace that would hold her place. A community that would not whisper. Medicine that would travel with her.
That is not a wish list. On World TB Day, that is the brief.
Tuberculosis is a treatable condition. If you have a persistent cough, unexplained weight loss, night sweats, or fatigue lasting more than two weeks, please seek assessment from a qualified healthcare professional as soon as possible.
